Our innovative portfolio of products is designed to help you meet challenges in the treatment of complex peripheral disease.

Improving Patient Outcomes

Backed by dedicated service, our Peripheral Arterial Disease (PAD) and AV Access solutions are designed to help improve patient outcomes.

Engineered for durability, accuracy, conformability, and thromboresistance to help you treat more cases.

EXPLORE OUR CBAS HEPARIN SURFACE TECHNOLOGY >

Designed for performance.

Products ideally suited to the unique needs of complex peripheral cases.
 

SEE OUR PRODUCTS' INSTRUCTIONS FOR USE >


SEE OUR PAD PRODUCTS IN ACTION >
 

SEE OUR AV ACCESS PRODUCTS IN ACTION >

Committed to responsive service, in-depth education, and extensive case support.
 

VISIT OUR MEDICAL MASTERY EDUCATIONAL PORTAL

Gore PAD Solutions: Innovation for Improved Outcomes in Complex Peripheral Disease

Our innovative PAD solutions are designed for treating all stages of complex peripheral disease and backed by dedicated service to help improve patient outcomes.

Learn more about our PAD Portfolio

Instructions for Use available here

GORE® TIGRIS® Vascular Stent

Delivers precise placement and conformability in complex anatomies.

 

GORE® VIABAHN® Endoprosthesis

Proven success treating long, complex lesions and in-stent restenosis.

 

GORE® PROPATEN® Vascular Graft

Powerful patency. A decade of performance.

Gore AV Access Solutions

Our innovative hemodialysis access solutions are designed to create and preserve vascular access, especially in complex cases. Our comprehensive product line is backed by dedicated service to help improve patient outcomes.

Learn more about our AV Access Portfolio

Instructions for Use available here

GORE® ACUSEAL Vascular Graft

Early cannulation. Immediate benefits.

 

GORE® Hybrid Vascular Graft

Access complex anatomy.

 

GORE® VIABAHN® Endoprosthesis

Complete coverage for complex cases.

Related information

Providing durable access in challenging presentations
 

Read the supplement >

Tackling Complex Cases in Dialysis Access

See the technology

Gore’s CBAS Heparin Surface, the proven heparin bonding technology for lasting thromboresistance, is used in many of our interventional and vascular surgery products. End-point covalent bonding keeps heparin anchored to the device, while the bioactive site remains free to interact with the blood to help prevent clotting.*

  • Proven Heparin Availability: Performance-ready heparin active site1,4*
  • Proven Heparin Bioactivity: Unmatched, persistent ability to take up antithrombin2,4*
  • Proven Lasting Thromboresistance: Improved surface hemocompatibility resulting from heparin availability and bioactivity1,2,3,4*

*See full CBAS Heparin Surface references

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.

Featured Gore Products with CBAS Heparin Surface

50% reduction in the risk of graft occlusion compared to standard ePTFE in Critical Limb Ischemia (CLI) patients 1
 

Learn more >


1. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.

The GORE® TIGRIS® Vascular Stent features Gore's CBAS Heparin Surface, designed to resist thrombus formation, a problem common in both bare metal and drug-eluting stents.
 

Learn more >

An Investigational Device Exemption (IDE) Clinical Study of the GORE® VIABAHN® Endoprosthesis with Propaten Bioactive Surface** in Japan demonstrated:

  • 88% 12-month primary patency in long, complex SFA lesions (n = 103)1
  • 21.8 cm average lesion length
  • 65.7% chronic total occlusions (CTOs)
  • 84.5% TASC II C&D lesions

 

Learn more >


** Propaten Bioactive Surface is synonymous with the CBAS Heparin Surface.

1. GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study demonstrated 12-month primary patency of 92% as defined by evidence of flow with no Target Lesion Revascularization (TLR). The same study demonstrated 88% 12-month primary patency when defined by PSVR of < 2.5 without a TLR.